News
Current report 34/2021 – Allocation of D-series shares
Allocation of D-series shares
Celon Pharma has completed its book – building process. Investors will be taking over all Offered Shares.
Celon Pharma has completed its book – building process. Investors will be taking over all Offered Shares.
Celon Pharma S.A. launches public offering of D-series shares
On 01 July 2021 Celon Pharma S.A. received the decision on approval of the prospectus by the Polish Financial Supervision Authority and published its prospectus in connection with its public offering of D-series shares (the “Offering”). The maximum price in the Offering was set at PLN 45 per share. The Company intends to issue up to 6,000,000 shares and obtain EUR 60 million to finance development of its clinical pipeline and for other corporate purposes, over the course of the next two years.
Current report 33/2021 – List of shareholders holding at least 5% of the votes at the Annual General Meeting of the Company held on June 29, 2021
List of shareholders holding at least 5% of the votes at the Annual General Meeting of the Company held on June 29, 2021
Current report 32/2021 – Resolutions adopted by the Annual General Meeting of Celon Pharma S.A. on June 29, 2021
Resolutions adopted by the Annual General Meeting of Celon Pharma S.A. on June 29, 2021
Current report 31/2021 – Resolution of the Annual General Meeting on the payment of the dividend
Resolution of the Annual General Meeting on the payment of the dividend
Current report 30/2021 – Supplementing the documentation for the Ordinary General Meeting of Celon Pharma S.A. convened to take place on June 29, 2021
Supplementing the documentation for the Ordinary General Meeting of Celon Pharma S.A. convened to take place on June 29, 2021
Current report 29/2021 – adoption of a resolution of the Company’s Management Board on amending the resolution on the share capital increase as part of its authorized capital
adoption of a resolution of the Company’s Management Board on amending the resolution on the share capital increase as part of its authorized capital
Current report 28/2021 – Signing of a letter of intent on commencing cooperation with Tarchomińskie Zakłady Farmaceutyczne S.A.
Signing of a letter of intent on commencing cooperation with Tarchomińskie Zakłady Farmaceutyczne S.A.
Current report 27/2021 – Status update of the phase II clinical trial on an esketamine-based drug in patients with bipolar depression
Status update of the phase II clinical trial on an esketamine-based drug in patients with bipolar depression
